Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) Director Jeffrey Albers sold 18,000 shares of the stock in a transaction on Friday, August 7th. The stock was sold at an average price of $104.55, for a total value of $1,881,900.00. Following the sale, the director directly owned 9,360 shares in the company, valued at approximately $978,588. This trade represents a 65.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Spyre Therapeutics Price Performance
SYRE stock traded up $0.42 during midday trading on Monday, reaching $105.33. The company had a trading volume of 822,679 shares, compared to its average volume of 999,524. Spyre Therapeutics, Inc. has a 1-year low of $14.51 and a 1-year high of $108.14. The stock has a 50 day moving average price of $91.86 and a 200-day moving average price of $66.16. The company has a market capitalization of $9.26 billion, a price-to-earnings ratio of -54.02 and a beta of 3.03.
Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.40. As a group, research analysts anticipate that Spyre Therapeutics, Inc. will post -2.62 earnings per share for the current year.
Analyst Upgrades and Downgrades
Get Our Latest Analysis on Spyre Therapeutics
Institutional Investors Weigh In On Spyre Therapeutics
Hedge funds have recently added to or reduced their stakes in the business. Summit Securities Group LLC bought a new stake in shares of Spyre Therapeutics in the first quarter worth $28,000. GAMMA Investing LLC increased its stake in shares of Spyre Therapeutics by 26.8% in the second quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock valued at $59,000 after buying an additional 140 shares during the period. KBC Group NV bought a new position in shares of Spyre Therapeutics during the first quarter worth about $69,000. Russell Investments Group Ltd. lifted its stake in shares of Spyre Therapeutics by 2,881.7% in the third quarter. Russell Investments Group Ltd. now owns 4,234 shares of the company’s stock worth $71,000 after acquiring an additional 4,092 shares during the period. Finally, Persistent Asset Partners Ltd acquired a new position in shares of Spyre Therapeutics in the fourth quarter worth approximately $74,000. 80.39% of the stock is currently owned by institutional investors and hedge funds.
About Spyre Therapeutics
Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.
Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.
Recommended Stories
- Five stocks we like better than Spyre Therapeutics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
